Literature DB >> 11927615

The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut.

Kenji Kabashima1, Tomomi Saji, Takahiko Murata, Miyako Nagamachi, Toshiyuki Matsuoka, Eri Segi, Kazuhito Tsuboi, Yukihiko Sugimoto, Takuya Kobayashi, Yoshiki Miyachi, Atsushi Ichikawa, Shuh Narumiya.   

Abstract

We used mice deficient in each of the eight types and subtypes of prostanoid receptors and examined the roles of prostanoids in dextran sodium sulfate-induced (DSS-induced) colitis. Among the prostanoid receptor-deficient mice, only EP4-deficient mice and not mice deficient in either DP, EP1, EP2, EP3, FP, IP, or TP developed severe colitis with 3% DSS treatment, which induced only marginal colitis in wild-type mice. This phenotype was mimicked in wild-type mice by administration of an EP4-selective antagonist (AE3-208). The EP4 deficiency impaired mucosal barrier function and induced epithelial loss, crypt damage, and aggregation of neutrophils and lymphocytes in the colon. Conversely, administration of an EP4-selective agonist (AE1-734) to wild-type mice ameliorated severe colitis normally induced with 7% DSS, while that of AE3-208 suppressed recovery from colitis and induced significant proliferation of CD4+ T cells. In vitro AE3-208 enhanced and AE1-734 suppressed the proliferation and Th1 cytokine production of lamina propria mononuclear cells from the colon. DNA microarray analysis revealed elevated expression of genes associated with immune response and reduced expression of genes with mucosal repair and remodeling in the colon of EP4-deficient mice. We conclude that EP4 maintains intestinal homeostasis by keeping mucosal integrity and downregulating immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927615      PMCID: PMC150928          DOI: 10.1172/JCI14459

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

Review 1.  The biology of chemokines and their receptors.

Authors:  D Rossi; A Zlotnik
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.

Authors:  J B Felder; B I Korelitz; R Rajapakse; S Schwarz; A P Horatagis; G Gleim
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

3.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

Authors:  O Morteau; S G Morham; R Sellon; L A Dieleman; R Langenbach; O Smithies; R B Sartor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 4.  Prostanoid receptors: structures, properties, and functions.

Authors:  S Narumiya; Y Sugimoto; F Ushikubi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

5.  Systemically derived large intestinal CD4(+) Th2 cells play a central role in STAT6-mediated allergic diarrhea.

Authors:  M N Kweon; M Yamamoto; M Kajiki; I Takahashi; H Kiyono
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

6.  Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper.

Authors:  E Carty; M De Brabander; R M Feakins; D S Rampton
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

7.  Effects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentration.

Authors:  A Wiercińska-Drapało; R Flisiak; D Prokopowicz
Journal:  Prostaglandins Other Lipid Mediat       Date:  1999-10       Impact factor: 3.072

8.  Prostanoids in human colonic mucosa: effects of inflammation on PGE(2) receptor expression.

Authors:  R Cosme; D Lublin; V Takafuji; K Lynch; J K Roche
Journal:  Hum Immunol       Date:  2000-07       Impact factor: 2.850

9.  Prostaglandin D2 as a mediator of allergic asthma.

Authors:  T Matsuoka; M Hirata; H Tanaka; Y Takahashi; T Murata; K Kabashima; Y Sugimoto; T Kobayashi; F Ushikubi; Y Aze; N Eguchi; Y Urade; N Yoshida; K Kimura; A Mizoguchi; Y Honda; H Nagai; S Narumiya
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

Review 10.  Eicosanoids and the large intestine.

Authors:  W Krause; R N DuBois
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-05       Impact factor: 3.072

View more
  163 in total

1.  Helminths and harmony.

Authors:  J V Weinstock; R Summers; D E Elliott
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

2.  Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis.

Authors:  Sundaram Ramasamy; Deanna D Nguyen; Michelle A Eston; Sayeda Nasrin Alam; Angela K Moss; Farzad Ebrahimi; Brishti Biswas; Golam Mostafa; Kathryn T Chen; Kanakaraju Kaliannan; Halim Yammine; Sonoko Narisawa; José Luis Millán; H Shaw Warren; Elizabeth L Hohmann; Emiko Mizoguchi; Hans-Christian Reinecker; Atul K Bhan; Scott B Snapper; Madhu S Malo; Richard A Hodin
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

Review 3.  Intestinal mucosal responses to microbial infection.

Authors:  Lars Eckmann; Martin F Kagnoff
Journal:  Springer Semin Immunopathol       Date:  2005-06-01

4.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

5.  Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice.

Authors:  James A Lin; Junji Watanabe; Nora Rozengurt; Ajay Narasimha; Martin G Martin; Jenny Wang; Jonathan Braun; Robert Langenbach; Srinivasa T Reddy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-04-25       Impact factor: 3.072

6.  Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.

Authors:  I Dey; M A Giembycz; K Chadee
Journal:  Br J Pharmacol       Date:  2009-01-23       Impact factor: 8.739

7.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

8.  Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

9.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

10.  Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.

Authors:  Elizabeth M Poole; Li Hsu; Liren Xiao; Richard J Kulmacz; Christopher S Carlson; Peter S Rabinovitch; Karen W Makar; John D Potter; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.